This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (27)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Renal Diseases, Other  • Prognosis/ Outcomes  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Associations Between Cardiovascular Disease Risk Factors and Clinical Outcomes

Meredith C. Foster, BA; Shih-Jen Hwang, PhD; Martin G. Larson, ScD; Nisha I. Parikh, MD, MPH; James B. Meigs, MD, MPH; Ramachandran S. Vasan, MD; Thomas J. Wang, MD; Daniel Levy, MD; Caroline S. Fox, MD, MPH

Arch Intern Med. 2007;167(13):1386-1392.

Background  Chronic kidney disease is defined by reduced estimated glomerular filtration rate (reduced eGFR) or by microalbuminuria (MA). Concordance between reduced eGFR and MA and associated cardiovascular disease (CVD) and all-cause mortality according to these definitions is uncertain.

Methods  Participants (n = 2966 [52.6% were women], mean age, 59 years) were drawn from the Framingham Offspring Cohort. Participants were classified into 4 groups based on the presence or absence of reduced eGFR (eGFR < 59 mL/min/1.73 m² in women, < 64 mL/min/1.73 m² in men or MA (spot urinary albumin to creatinine ratio of at least 30 mg/g). Cox proportional hazard models were used to determine the combined risk of CVD events and all-cause mortality for each group.

Results  Of the participants, 9.9% (n = 295) had reduced eGFR, and 12.2% (n = 362) had MA. Among those with reduced eGFR, 28% had MA. Those with reduced eGFR and with MA were at increased risk for combined CVD and all-cause mortality compared with those with neither condition (hazard ratio [HR] 1.7, 95% confidence interval [CI], 1.1-2.4; P = .009), whereas those with reduced eGFR and without MA and those without reduced eGFR and with MA had similar HRs (1.3 and 1.2, respectively). Those with reduced eGFR and with MA, as well as those with reduced eGFR and without MA, were at significantly increased risk of all-cause mortality (HR 2.2 [95% CI, 1.4-3.6] and HR 1.7 [95% CI, 1.1-2.6], respectively).

Conclusions  Reduced eGFR and MA are relatively common conditions with different risk factor profiles. The coexistence of reduced eGFR and MA was present in 2.8% of the study sample and conferred substantial increased risk for CVD and all-cause mortality, in part because of a heavy burden of CVD risk factors.

Author Affiliations: National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts (Ms Foster and Drs Hwang, Levy, and Fox); the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (Ms Foster and Drs Hwang, Levy, and Fox); Department of Mathematics and Statistics (Drs Larson and Parikh) and School of Medicine (Drs Parikh and Vasan), Boston University, Boston, Massachusetts; General Medicine Division, Department of Medicine (Dr Meigs), and Division of Cardiology (Dr Wang), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston (Dr Fox).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cystatin C, Albuminuria, and Mortality Among Older Adults With Diabetes
de Boer et al.
Diabetes Care 2009;32:1833-1838.
ABSTRACT | FULL TEXT  

Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes
Ninomiya et al.
J. Am. Soc. Nephrol. 2009;20:1813-1821.
ABSTRACT | FULL TEXT  

Prediction, Progression, and Outcomes of Chronic Kidney Disease in Older Adults
Anderson et al.
J. Am. Soc. Nephrol. 2009;20:1199-1209.
ABSTRACT | FULL TEXT  

Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15)
Yokoyama et al.
Nephrol Dial Transplant 2009;24:1212-1219.
ABSTRACT | FULL TEXT  

Kidney Stones and the Risk for Chronic Kidney Disease
Rule et al.
CJASN 2009;4:804-811.
ABSTRACT | FULL TEXT  

A critical evaluation of chronic kidney disease--should isolated reduced estimated glomerular filtration rate be considered a 'disease'?
Poggio and Rule
Nephrol Dial Transplant 2009;24:698-700.
FULL TEXT  

The Case for Using Albuminuria in Staging Chronic Kidney Disease
Gansevoort and de Jong
J. Am. Soc. Nephrol. 2009;20:465-468.
FULL TEXT  

Perspectives on eGFR reporting from the Interface between Primary and Secondary Care
Cheung and Bhandari
CJASN 2009;4:258-260.
ABSTRACT | FULL TEXT  

Early identification and management of chronic kidney disease: summary of NICE guidance
Crowe et al.
BMJ 2008;337:a1530-a1530.
FULL TEXT  

Trends in Diabetes, High Cholesterol, and Hypertension in Chronic Kidney Disease Among U.S. Adults: 1988-1994 to 1999-2004
Fox and Muntner
Diabetes Care 2008;31:1337-1342.
ABSTRACT | FULL TEXT  

Fact or fiction of the epidemic of chronic kidney disease--let us not squabble about estimated GFR only, but also focus on albuminuria
de Jong and Gansevoort
Nephrol Dial Transplant 2008;23:1092-1095.
FULL TEXT